The high levels of GPC3 detected in HCC and the absence or very low levels in normal and non-malignant liver make GPC3 a promising TAA candidate for ligand-conjugated nanoparticle-based targeted therapies. This evidence concerns the gene GPC3 and hepatocellular carcinoma.